By Mill Chart
Last update: Aug 5, 2025
Pacira BioSciences Inc (NASDAQ:PCRX) reported its second-quarter 2025 financial results, delivering a mixed performance relative to analyst expectations. While earnings per share (EPS) slightly surpassed estimates, revenue fell short of projections, contributing to a muted market reaction in after-hours trading.
Following the earnings release, Pacira’s stock showed no immediate movement in after-hours trading, indicating investor neutrality. Over the past month, shares have declined by 2.76%, though they have seen a slight rebound in the last week (+4.3%). The lack of a strong reaction suggests that while the EPS beat is a positive, the revenue miss may be tempering enthusiasm.
The company emphasized progress in its "5x30" growth strategy, which includes expanding its non-opioid pain management portfolio. Key highlights from the release include:
Given the revenue miss in Q2, investors will likely monitor whether Pacira can regain momentum in the second half of the year to meet full-year projections.
For a deeper dive into Pacira’s earnings history and future estimates, visit the earnings and estimates page.
Disclaimer: This article is for informational purposes only and does not constitute investment advice.
22.54
-0.4 (-1.74%)
Find more stocks in the Stock Screener